Abstract
Epithelioid hemangioendothelioma (EHE) is an ultra-rare cancer driven by the YAP-CAMTA1 fusion. Based on the link of the fusion to the MEK pathway SARC33 was performed. It is a phase 2 trial examining trametinib that missed its primary objective by RECIST, but demonstrated patient reported outcome benefits in improved pain.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Clinical cancer research : an official journal of the American Association for Cancer Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.